An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”
- Equal contributors
Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada
BMC Infectious Diseases 2013, 13:54 doi:10.1186/1471-2334-13-54Published: 30 January 2013
To update a cost-effectiveness analysis of rotavirus vaccination in the Netherlands previously published in 2011.
The rotavirus burden of disease and the indirect protection of older children and young adults (herd protection) were updated.
When updated data was used, routine infant rotavirus vaccination in the Netherlands would potentially become an even more cost-effective strategy than previously estimated with the incremental cost per QALY at only €3,000-4,000. Break-even total vaccination costs were indicated at €92–122, depending on the applied threshold.
We concluded that the results on potentially favourable cost-effectiveness in the previous study remained valid, however, the new data suggested that previous results might represent an underestimation of the economic attractiveness of rotavirus vaccination.